CAR-T therapy shows promise in clinical trial ...

The research is happening at Roswell Park Comprehensive Cancer Center.

Lab-grown dopamine cells show early success in Parkinson’s patients, improving movement and offering a new treatment path.

Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy ...

Novo Nordisk will be happy with the results after Pfizer has dropped two SCD assets in recent years. Credit: JHVEPhoto / ...

After six weeks in the hospital, 23‑year‑old Daniel Cressy leaves with hope for a functional cure and a future where he can ...

Cerebral Palsy Center reports Kidswell Bio is advancing stem cell therapy for cerebral palsy in the U.S., focusing on cells ...

CAR-T cell therapy has spread into earlier lines of care over the last ten years, going beyond heavily pretreated populations ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...

CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...

Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.